Skip to nav Skip to content

Natarajan Raghunand, PhD

Program: Metabolism and Physiology

Research Program: Molecular Medicine Program

View Lab Page

Google Scholar Profile


  • Overview


    • Metabolism and Physiology
    • Molecular Medicine Program

    Education & Training


    • Texas A&M University, PhD - Chemical Engineering
    • Colorado State University, MS - Chemical Engineering
  • Research Interest

    Dr. Natarajan Raghunand's research focus is on the development of clinically translatable radiologic biomarkers for the management of cancer. Collaborative clinical-translational research projects in his group include deep learning to predict optimal dose maps for stereotactic radiation treatment of breast cancer metastases to the brain, machine learning on pre-operative digital pathology and multiplexed immunofluorescence to predict upstaging of DCIS, ferumoxytol-enhanced MRI to guide immunotherapy of cancer, and multiparametric MRI to guide adaptive therapy of recurrent high-grade glioma.

  • Publications

    • Ravi H, Hawkins SH, Stringfield O, Pereira M, Chen DT, Enderling H, Michael Yu HH, Arrington JA, Sahebjam S, Raghunand N. Rules-based Volumetric Segmentation of Multiparametric MRI for Response Assessment in Recurrent High-Grade Glioma. Res Sq. 2023 Sep. Pubmedid: 37790451. Pmcid: PMC10543497.
    • Arias-Lorza AM, Costello JR, Hingorani SR, Von Hoff DD, Korn RL, Raghunand N. Tumor Response to Stroma-Modifying Therapy: Magnetic Resonance Imaging Findings in Early-Phase Clinical Trials of Pegvorhyaluronidase alpha (PEGPH20). Res Sq. 2023 Sep. Pubmedid: 37720027. Pmcid: PMC10503830.
    • Ravi H, Arias-Lorza AM, Costello JR, Han HS, Jeong DK, Klinz SG, Sachdev JC, Korn RL, Raghunand N. Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer. Radiol Imaging Cancer. 2023 Mar.5(2):e220022. Pubmedid: 36734848. Pmcid: PMC10077095.
    • Weinfurtner RJ, Abdalah M, Stringfield O, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Latifi K, Niell B, Montejo M, Raghunand N. Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER/PR+ HER2− Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy. J Breast Imaging. 2022 May.4(3):273-284. Pubmedid: 36686407. Pmcid: PMC9851176.
    • Youssef I, Poch M, Raghunand N, Pow-Sang J, Johnstone PAS. Analysis of MRI radiomic pelvimetry and correlation with margin status after robotic prostatectomy. Can J Urol. 2022 Feb.29(1):10976-10978. Pubmedid: 35150217.
    • Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer. 2022 Feb.22(2):e214-e223. Pubmedid: 34384695.
    • Kingsley JL, Costello JR, Raghunand N, Rejniak KA. Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations. PLoS Comput Biol. 2021 Jul.17(7):e1009206. Pubmedid: 34310608. Pmcid: PMC8341701.
    • Niell BL, Abdalah M, Stringfield O, Raghunand N, Ataya D, Gillies R, Balagurunathan Y. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk. Ajr Am J Roentgenol. 2021 Jul.217(1):64-75. Pubmedid: 32876474. Pmcid: PMC9801515.
    • Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021 Jan.31(1):36-49. Pubmedid: 32689909. Pmcid: PMC7864115.
    • Mazin A, Hawkins SH, Stringfield O, Dhillon J, Manley BJ, Jeong DK, Raghunand N. Identification of sarcomatoid differentiation in renal cell carcinoma by machine learning on multiparametric MRI. Sci Rep. 2021 Feb.11(1):3785. Pubmedid: 33589715. Pmcid: PMC7884398.
    • Pandey S, Snider AD, Moreno WA, Ravi H, Bilgin A, Raghunand N. Joint total variation-based reconstruction of multiparametric magnetic resonance images for mapping tissue types. Nmr Biomed. 2021 Dec.34(12):e4597. Pubmedid: 34390047.
    • Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
    • Lorza AMA, Ravi H, Philip RC, Galons JP, Trouard TP, Parra NA, Von Hoff DD, Read WL, Tibes R, Korn RL, Raghunand N. Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin. Sci Rep. 2020 Sep.10(1):14449. Pubmedid: 32879326. Pmcid: PMC7468301.
    • Glazar DJ, Grass GD, Arrington JA, Forsyth PA, Raghunand N, Yu HM, Sahebjam S, Enderling H. Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma. J Clin Med. 2020 Jun.9(7). Pubmedid: 32605050. Pmcid: PMC7409184.
    • Stringfield O, Arrington JA, Johnston SK, Rognin NG, Peeri NC, Balagurunathan Y, Jackson PR, Clark-Swanson KR, Swanson KR, Egan KM, Gatenby RA, Raghunand N. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme. Tomography. 2019 Mar.5(1):135-144. Pubmedid: 30854451. Pmcid: PMC6403044.
    • Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter AB, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Sarkaria JN, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR. ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach. Am J Clin Oncol. 2019 Aug.42(8):655-661. Pubmedid: 31343422. Pmcid: PMC7416695.
    • Jeong D, Raghunand N, Hernando D, Poch M, Jeong K, Eck B, Dhillon J. Quantification of sarcomatoid differentiation in renal cell carcinoma on magnetic resonance imaging. Quant Imaging Med Surg. 2018 May.8(4):373-382. Pubmedid: 29928602. Pmcid: PMC5989092.
    • Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget. 2017 Nov.8(60):102511-102520. Pubmedid: 29254266. Pmcid: PMC5731976.
    • Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget. 2017 Jun. Pubmedid: 28620142.
    • Ramanathan RK, Korn R, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J, Hendriks BS, Drummond DC, Bayever E, Fitzgerald JB. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study. Clin Cancer Res. 2017 Jul.23(14):3638-3648. Pubmedid: 28159813.
    • Landowski TH, Guntle GP, Zhao D, Jagadish B, Mash EA, Dorr RT, Raghunand N. Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol. 2016 Jun.9(3):228-235. Pubmedid: 27267841. Pmcid: PMC4907896.
    • Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin S, Gladkov O, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clin Cancer Res. 2016 Jun.22(12):2848-2854. Pubmedid: 26813359. Pmcid: PMC7787348.
    • Jagadish B, Ozumerzifon TJ, Roberts SA, Hall GB, Mash EA, Raghunand N. IMPROVED SYNTHESIS OF 10-(2-ALKYLAMINO-2-OXOETHYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID DERIVATIVES BEARING ACID-SENSITIVE LINKERS. Synthetic Commun. 2014 Jan.44(3). Pubmedid: 24363464. Pmcid: PMC3866964.
    • Rajaraman S, Rodriguez JJ, Raghunand N. Response to Andrew Melbourne, "comment on: automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques". Magn Reson Imaging. 2013 Feb.31(2):326-328. Pubmedid: 22925607.
    • Guntle GP, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N. Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Transl Oncol. 2012 Jun.5(3):190-199. Pubmedid: 22741038. Pmcid: PMC3384273.
    • Jagadish B, Guntle GP, Zhao D, Gokhale V, Ozumerzifon TJ, Ahad AM, Mash EA, Raghunand N. Redox-active magnetic resonance imaging contrast agents: studies with thiol-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid derivatives. J Med Chem. 2012 Dec.55(23):10378-10386. Pubmedid: 23148501. Pmcid: PMC3607631.
    • Rajaraman S, Rodriguez JJ, Graff C, Altbach MI, Dragovich T, Sirlin CB, Korn RL, Raghunand N. Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. Magn Reson Imaging. 2011 Jun.29(5):668-682. Pubmedid: 21531108. Pmcid: PMC3100446.
    • Jagadish B, Brickert-Albrecht GL, Nichol GS, Mash EA, Raghunand N. On the Synthesis of 1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane. Tetrahedron Lett. 2011 Apr.52(17):2058-2061. Pubmedid: 21516221. Pmcid: PMC3079211.
    • Raghunand N, Guntle GP, Gokhale V, Nichol GS, Mash EA, Jagadish B. Design, synthesis, and evaluation of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid derived, redox-sensitive contrast agents for magnetic resonance imaging. J Med Chem. 2010 Sep.53(18):6747-6757. Pubmedid: 20722424. Pmcid: PMC2941433.
    • Raghunand N. Tissue pH measurement by magnetic resonance spectroscopy and imaging. Methods Mol Med. 2006.124:347-364. Pubmedid: 16506429.
    • Gillies R, Raghunand N, Garcia-Martin M, Gatenby R. pH imaging. A review of pH measurement methods and applications in cancers. Ieee Eng Med Biol Mag. 2004 Sep.23(5):57-64. Pubmedid: 15565800.
    • Raghunand N, Gatenby R, Gillies R. Microenvironmental cellular consequences of altered blood flow in tumours. Br J Radiol. 2003 Dec.76:S11-S22. Pubmedid: 15456710.
    • Jennings D, Hatton B, Guo J, Galons J, Trouard T, Raghunand N, Marshall J, Gillies R. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia. 2002 May.4(3):255-262. Pubmedid: 11988845. Pmcid: PMC1531699.
    • Raghunand N, Gillies R. pH and chemotherapy. Novartis Found Symp. 2001.240:199-211. Pubmedid: 11727930.
    • Gillies RJ, Scherer PG, Raghunand N, Okerlund LS, Martinez-Zaguilan R, Hesterberg L, Dale BE. Iteration of hybridoma growth and productivity in hollow fiber bioreactors using 31P NMR. Magn Reson Med. 1991 Mar.18(1):181-192. Pubmedid: 2062229.
  • Grants

    • Title: SOW# 01: A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
      Sponsor: Imaging Endpoints
      PI: Raghunand, N.
    • Title: SOW#02: A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors
      Sponsor: Imaging Endpoints
      PI: Raghunand, N.
    • Title: Radiomics and Pathomics to Predict Upstaging of DCIS
      Sponsor: Nat Institutes of Health
      PI (Contact): Niell, B., PI (MPI): Raghunand, N.

Find a Researcher Search